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Deregulated ERK signaling drives cancer growth. Normally, ERK
activity is self-limiting by the rapid inactivation of upstream ki-
nases and delayed induction of dual-speciﬁcity MAP kinase phos-
phatases (MKPs/DUSPs). However, interactions between these
feedback mechanisms are unclear. Here we show that while the
MKP, DUSP5, both inactivates and anchors ERK in the nucleus,
it paradoxically increases and prolongs cytoplasmic ERK activity.
The latter effect is caused, at least in part, by the relief of ERK-
mediated RAF inhibition. The importance of this spatiotempo-
ral interaction between these distinct feedback mechanisms is
illustrated by the fact that expression of oncogenic BRAFV600E, a
feedback-insensitive mutant RAF kinase, reprograms DUSP5 into a
cell-wide ERK inhibitor that facilitates cell proliferation and trans-
formation. In contrast, DUSP5 deletion causes BRAFV600E-induced
ERK hyperactivation and cellular senescence. Thus, feedback inter-
actions within the ERK pathway can regulate cell proliferation and
transformation, and suggest oncogene-speciﬁc roles for DUSP5 in
controlling ERK signaling and cell fate.
ERK j MAPK j MKP j DUSP j Signaling
Introduction
Activation of the prototypic MAPK (mitogen-activated protein
kinase), ERK (extracellular signal-regulated kinase), regulates a
range of cell fate decisions including differentiation, proliferation
and death (1, 2). Most stimuli engage ERK signaling by activating
RAS GTPases, which promote the dimerization and activation
of RAF kinases. RAF then phosphorylates and activates MEK
(MAPK/ERK kinase), which in turn phosphorylates both thre-
onine and tyrosine residues within a signature T-E-Y motif to
activate ERK (2, 3). Under physiological conditions, ERK activity
is self-limiting by the rapid phosphorylation and inhibition of
upstream components, such as RAF kinases (4–6), RAS exchange
factors (7) and receptor tyrosine kinases (RTKs) (8, 9), but also by
delayed induction of dual-specificity MAP kinase phosphatases
(MKPs/DUSPs), which dephosphorylate and inactivate ERK (10,
11). Whether these temporally distinct negative feedback loops
have cooperative or distinct roles in regulating ERK signaling is
currently unclear.
Oncogenic mutations in RAS (RASmut) or a V600E substitu-
tion in BRAF frequently drive tumor progression through con-
stitutive downstreamMEK-ERK activation (12). ERK-inhibitory
proteins, such as the MKP/DUSPs, are therefore often assumed
to be tumor suppressors, but both decreased and increased
MKP/DUSP expression is linked to tumor progression in differ-
ent contexts (13). These observations may, at least in part, be
explained by evidence showing that high intensity ERK activa-
tion in some cell and tumor types engages tumor suppressive
mechanisms, such as senescence (14–18). In such circumstances,
the attenuation of ERK signaling by MKP/DUSPs may actually
promote tumor progression (16, 17).
DUSP5, a nuclear-localized member of the MKP/DUSP
family, is induced in response to ERK activation (19, 20)
and specifically dephosphorylates and anchors ERK in the
nucleus (21). We recently established that Dusp5 knockout
(KO) mice are sensitized to HRASQ61L-driven DMBA/TPA
(7,12-Dimethylbenz[a]anthracene/12-O-tetra-decanoylphorbol-
13-acetate)-initiated skin carcinogenesis, due to increased
nuclear ERK activity and ERK-dependent SerpinB2 expression
(22). Furthermore, the downregulation of DUSP5 in gastric and
prostate cancers is also associated with a poor prognosis (23,
24), suggesting that DUSP5 can function as a tumor suppressor.
In contrast, DUSP5 expression is commonly retained or even
enhanced in BRAFV600E-driven colorectal, melanoma and
thyroid cancer cell lines and tumors (25–27). This suggests that
DUSP5 may either promote or limit the oncogenic potential of
ERK signaling, depending on cellular context.
Here, we report that in addition to its role in the nuclear
inactivation of ERK, DUSP5 increases RAF, MEK and ERK
activity in the cytoplasm. This latter effect is caused by the relief
of upstream kinase inhibition, and depends on both the turnover
rate of DUSP5 and its ability to sequester inactive ERK in the
nucleus. Expression of the BRAFV600E oncoprotein, which is
insensitive to feedback inhibition, alters the function ofDUSP5 to
become a cell-wide inhibitor of ERK, which in turn enables cells
to avoid ERK hyperactivation and senescence. These data may
explain why DUSP5 may be associated with tumor suppression
or promotion in different tumor types.
Signiﬁcance
The RAF-ERK kinase pathway drives cell proliferation and
cancer growth. ERK kinase activity is terminated by dual-
speciﬁcity MAPK phosphatases (MKP/DUSPs), which are often
assumed to be tumor suppressors. We demonstrate that the
MKP, DUSP5, terminates nuclear ERK signaling, but surpris-
ingly promotes ERK activation in the cytoplasm by relieving
feedback inhibition of upstream kinases. Cancer-causing RAF
kinase mutations, which occur in 8% of tumors and are
refractory to feedback inhibition, reprogramDUSP5 to become
a cell-wide attenuator of ERK signaling that prevents cellular
senescence and promotes oncogenic transformation. Our re-
sults establish that interactions between feedback loops in the
ERK cascade control localized signal-promotion or suppression,
which in turn govern cell proliferation and transformation.










































































































































Submission PDFFig. 1. DUSP5 propagates cytoplasmic ERK signaling. Serum-starved primary MEFs from wild-type (WT) or DUSP5 knockout (KO) mice were infected witheither 0.3-3.0 pfu/nl Ad ERK-responsive EGR1 promoter-driven DUSP5-Myc (DUSP5) or a KIM mutant of DUSP5-Myc (DUSP5R53/54A) and stimulated with 20%FBS for times indicated. (A) Representative confocal images of p-ERK and ERK are shown. Scale bar = 60 μm. (B) High content microscopy was used to quantify
>104 cells per condition, per experiment for levels of Myc tag, nuclear (Nuc) or cytoplasmic (Cyt) p-ERK intensity, or nuclear:cytoplasmic ratio (N:C) of total
ERK ﬂuorescence. Data are normalized mean AFU values ±SEM, n = 4-8, *p<0.05, **p<0.01 comparing WT vs KO using 2-way repeated measures ANOVA and
Bonferroni post-test. Note: KO data are identical in upper and lower plots. (C) Western blots of whole cell lysates are shown for total and TEY activation loop
phosphorylated (p-) ERK, β-tubulin and DUSP5. A representative blot is shown from n=3 similar experiments; blot quantiﬁcation is shown in Fig. S1C.
Results
DUSP5 controls both nuclear and cytoplasmic ERK activity.We
have previously demonstrated that DUSP5 causes both nuclear
accumulation and dephosphorylation of ERK in mouse embry-
onic fibroblasts (MEFs) when stimulated with the phorbol ester,
TPA (22). These localized effects were revealed using confocal
and high content microscopy (HCM) (22). We therefore used
similar methodology to compare the effects of DUSP5 on ERK
responses to serum and growth factors.
Fetal bovine serum (FBS) stimulation of serum-starved pri-
mary wild-type (WT) MEFs rapidly elicited high levels of dually
(pT-E-pY) phosphorylated ERK (p-ERK) in the nucleus and
cytoplasm (from 5-60 min), followed by nuclear dephosphory-
lation of ERK and a prolonged phase (120-360 min) of lower-
intensity cytoplasmic p-ERK signaling (30-50% of peak values)
(Fig. 1A, 1B, S1A and S1B). This is consistent with studies in
several cell types showing that prolonged growth factor or serum
stimulus typically causes transient nuclear but sustained cytoplas-
mic ERK activation (28, 29). Maximal increases in ERK nuclear
accumulation (reflected by the nuclear:cytoplasmic, N:C, ratio of
total ERK) occurred concurrently with the onset of nuclear ERK
dephosphorylation, (Fig. 1A, 1B and S1B) andDUSP5 expression
(Fig. 1C), suggesting that DUSP5 may be responsible for the
nuclear accumulation and dephosphorylation of ERK (21, 22).
In agreement with this hypothesis, Dusp5 deletion both reduced
the N:C ERK ratio and elevated nuclear p-ERK levels (Fig.
1A, 1B and S1A). Surprisingly, Dusp5 deletion also reduced the
amplitude of the prolonged (240-360 min) serum-induced cyto-
plasmic p-ERK response, suggesting that in addition to its nuclear
inactivation of ERK, DUSP5may also promote cytoplasmic ERK
activation (Fig. 1A and 1B).
Previous reports show that constitutive overexpression of
DUSP5 causes the constitutive nuclear accumulation and dephos-
phorylation of ERK (21). We therefore hypothesized that the
propagation of cytoplasmic p-ERK levels (Fig. 1A and B) may
arise because DUSP5 is induced in response to ERK activity
(19, 20). To test this, we rescued DUSP5 expression in Dusp5
KO MEFs using adenovirus (Ad) vectors containing an ERK-
responsive 1.2 kb EGR1 immediate early gene promoter to drive
DUSP5-Myc expression (22). Low titer (0.3 pfu/nl) Ad DUSP5-
Myc restored transient DUSP5 expression (Fig. 1C), as well as
corresponding changes ERK N:C ratio, ERK nuclear dephos-
phorylation and the cytoplasmic rebound in p-ERK (Fig. 1A, 1B,
and S1). The addition of higher titer Ad DUSP5-Myc (up to 3
pfu/nl) caused supraphysiological DUSP5 expression (Fig. 1C)
and exaggerated all endpoints of ERK regulation, including the
propagation of cytoplasmic ERK activity (Fig. 1A, 1B, and S1B).
These effects of Dusp5 KO and rescue on cytoplasmic p-ERK
were also reflected in Western blots of whole cell lysates, most
likely because the cytoplasm occupies a much greater volume of
MEFs than the nucleus (compare Fig. 1B, 1C and S1C). Negative
control experiments using Ad to express an R53/54A kinase inter-
action motif (KIM) mutant of DUSP5-Myc that is unable to bind
to ERK and driven by the same EGR1 promoter (21, 22), failed
to influence ERK responses at any titer, indicating the necessity
of DUSP5 association with ERK (Fig. 1B and S1B). Plotting of
single cell data revealed that increased cytoplasmic p-ERK levels
after 240 min FBS stimulus correlated with increases in both
DUSP5-Myc (but not DUSP5R53/54A-Myc) expression levels and
ERK N:C ratio, indicating that these effects are cell-autonomous
(Fig. S2).
Our previous studies, using TPA stimulation of MEFs with-
out serum starvation, showed that endogenous levels of DUSP5
suppressed nuclear ERK activity, but did not alter cytoplas-
mic p-ERK responses (22). We repeated these experiments, but
included Ad DUSP5-Myc or Ad DUSP5R53/54A-Myc to rescue
expression from sub- to supraphysiological levels in Dusp5 KO
MEFs. DUSP5-Myc, but not DUSP5R53/54A-Myc, caused dose-
dependent nuclear dephosphorylation and anchoring of ERK in
response to TPA, but cytoplasmic p-ERK responses were only
increased at supraphysiological levels of DUSP5 (Fig. S3A).
DUSP5-Myc over-expression also increased cytoplasmic p-ERK
responses to nerve growth factor (NGF) stimulation in rat PC12











































































































































Fig. 2. DUSP5 propagates ERK signaling by increasing RAF and MEK
activity.Wild-type (WT) and Dusp5 knockout (KO) primary MEFs were in-
fected with 0.3-3.0 pfu/nl Ad EGR1 promoter-driven DUSP5-Myc (Ad DUSP5)
as indicated. (A) MEFs were stimulated for 360 min with 20% FBS. Western
blots of whole cell lysates were probed for phospho (p-) sites on ERK
(TEY activation loop), MEK (Ser217/221), CRAF (Ser338) and p90RSK (Thr
359/Ser363) as well as total kinase levels and β-tubulin. Normalized blot
quantiﬁcation is shown ±SEM, n = 4. *p<0.05, **p<0.01 comparing KO vs
all columns using 1-way ANOVA and Dunnett's post-test. (B) MEFs were
stimulated either with 20% FBS for 360 min or 50 ng/ml EGF for 5 min prior
to lysis and pull down of GTP-RAS using the RAS-binding domain (RBD) of
CRAF. Input levels of total RAS in whole cell lysates and levels of GTP-RAS in
the pull down were measured by Western blotting. Normalized mean blot
quantiﬁcation of GTP-RAS is shown ±SEM, n = 3. (C) MEFs were stimulated
with 20% FBS for 120 min prior to addition of either DMSO vehicle or 5
μM PD0325901 MEK inhibitor for times indicated. Levels of Myc-tag and
whole-cell levels of p-ERKwere measured using high content microscopy.
Data shown are normalized population AFU values, n=3, ±SEM.
of DUSP5 - the maintenance or propagation of cytoplasmic p-
ERK signaling - that is cell autonomous, dose-dependent and
reliant upon association with ERK via the KIM domain.
DUSP5 propagates ERK signaling by increasing RAF and
MEK activation. To determine how DUSP5 may cause increased
ERK signaling, we examined the effects of Dusp5 deletion and
rescue on the core ERK pathway components; CRAF, MEK
and ERK, as well as the ERK substrate, p90 ribosomal S6 ki-
nase (p90RSK), after 360 min FBS stimulus. Whilst only p-ERK
levels showed a very obvious and substantial reduction in levels
following Dusp5 deletion, p-CRAF levels were also significantly
reduced, and Ad DUSP5-Myc rescue caused clear and dose-
dependent increases in the levels of all four phospho kinases
measured (Fig. 2A). It is likely that the more readily detectable
differences in p-ERK levels reflects the greater relative abun-
dance of ERK compared to the other kinases and because of
signal amplification through the RAF-MEK-ERK cascade (30).
Comparisons of MEK and ERK responses to FBS in fractionated
lysates showed that DUSP5 significantly increased cytoplasmic
p-MEK levels without influencing its localization or expression,
while p-ERK responses echoed those observed in our microscopy
assays (compare Fig. S4 and Fig. 1B). Strikingly, DUSP5 did not
influence FBS-induced RAS activation, even when expressed at
supraphysiological levels (Fig 2B). In contrast, elevated RAS-
GTP was readily detected in positive control samples stimulated
with epidermal growth factor (EGF) for 5 min (Fig. 2B). Whilst it
is possible that there could be highly localized or subtle changes
in RAS activation that we cannot measure in whole cell lysates,
the data suggest that DUSP5 causes major effects on ERK phos-
phorylation by promoting pathway activity downstream of RAS.
To investigate the possibility that DUSP5 could also pro-
mote ERK activity by attenuating other ERK phosphatases, we
compared the rate of ERK dephosphorylation after 120 min
FBS stimulus and addition of a specific MEK inhibitor (MEKi),
PD0325901, under conditions of Dusp5 deletion and rescue. A
complete loss of p-ERK was observed within 8 min following
MEKi addition, irrespective of DUSP5 expression level (Fig.
2C). We were also unable to detect differences in p-ERK half-
life under these conditions, which is likely due to the very high
constitutive rates of ERKdephosphorylation observed even in the
absence of DUSP5 expression. These results exclude the possi-
bility that DUSP5 could promote p-ERK signaling over several
hours by attenuating the activity of other ERK phosphatases,
and indicate that continuous MEK activity is required for the
propagation of ERK signaling by DUSP5. These data are also
supported by our previous studies showing that Dusp5 KO does
not change either serum or TPA-induced expression of other
ERK-regulatoryMKP/DUSPs inMEFs (DUSP4, 6, 7 and 9) (22).
Knock-down of DUSP5 in some cancer cell lines has been
reported to influence AKT phosphorylation (31), suggesting
DUSP5 may influence additional RAS-effector pathways. We
therefore compared FBS-induced activation of the ERK and
PI3K-AKT pathways by measuring p-AKT and p-ERK levels in
Dusp5 KO and rescue experiments. Whilst p-ERK levels were
again increased by DUSP5-Myc expression, p-AKT levels were
unchanged in the same cells, indicating that in MEFs, the effects
of DUSP5 are unlikely to be mediated by changes in the activity
of this alternative RAS effector pathway (Fig. S3C). These results
are also consistent with our previous studies showing that Dusp5
deletion does not influence JNK or p38 MAPK responses to FBS
or TPA stimuli (22). Thus, DUSP5 is most likely able to increase
the cytoplasmic activity of RAF,MEK and ERKwithout invoking
pathway cross-talk.
DUSP5 nuclear localization controls cytoplasmic ERK phos-
phorylation.Our experiments revealing that DUSP5 can prolong
ERK signaling raise the question of whether other MKP/DUSPs
might also exhibit this behavior. DUSP6 (also known as MKP-
3/Pyst1) is analogous to DUSP5 in its ERK-dependent promoter
regulation (32), ERK substrate specificity (33), sequestration of











































































































































Fig. 3. The DUSP5 nuclear localization signal is required for propagation of cytoplasmic p-ERK. Primary Dusp5 knockout (KO) MEFs were infected with
0.3-3 pfu/nl Ad EGR1 promoter-driven DUSP5-Myc (Ad DUSP5), a nuclear localization sequence mutant of DUSP5-Myc or DUSP6-Myc (Ad DUSP5 NLS and Ad
DUSP6, respectively), and stimulated with 20% FBS. (A) Representative high content microscopy images show cells infected with 3 pfu/nl Ad DUSP-Myc prior
to stimulation and staining for both TEY phosphorylated (p-) ERK and Myc-tag. <1% imaged area per condition per experiment is shown. Scale bar = 100 μm.
(B) Scatterplots show single cell comparisons of nuclear versus cytoplasmic levels of Myc tag (top), whole-cell Myc-tag versus whole-cell p-ERK levels (middle)
or ERK nuclear:cytoplasmic (N:C) ratio versus whole-cell p-ERK levels, from a single representative experiment of n = 4 comparing cells infected with 3 pfu/nl
Ad DUSP and stimulated for 180 min with FBS. All non-ratio values are shown in raw AFU per cell. (C) Plots show average nuclear (Nuc) p-ERK, cytoplasmic
(Cyt) p-ERK and whole cell Myc levels in cells stimulated with FBS. Data shown are mean, normalized AFU levels ±SEM, n = 4. Note: KO data are identical in
each row and are shown in each plot to clarify the effects of Ad DUSP-Myc expression in the Dusp5-deleted cells.
cytoplasm due to an N-terminal nuclear export sequence (33, 34),
while a nuclear localization sequence (NLS) close to the KIM
causes DUSP5 to accumulate in the nucleus (21).
To test whether DUSP5 effects on cytoplasmic p-ERK were
dependent on its nuclear localization, we used the EGR1 pro-
moter in identical Ad backbone vectors to enable a direct com-
parison of DUSP5-Myc with DUSP6-Myc or an NLS mutant
of DUSP5-Myc (DUSP5NLS), which impedes nuclear import but
maintains catalytic and anchoring functions (21). FBS stimulation
of Dusp5 KO cells infected with Ad DUSP5-Myc, DUSP5NLS-
Myc or DUSP6-Myc induced comparable levels of expression but
with different localization; DUSP5-Myc was almost exclusively
nuclear, DUSP6-Myc was chiefly cytoplasmic, while DUSP5NLS-
Myc was evenly distributed (Fig. 3A and 3B), which is consistent
with previous reports using these ORFs driven by constitutive
promoters (21, 34). As expected, DUSP5-Myc expression led to
elevated ERK N:C ratio, but maintained high levels of p-ERK
per cell (Fig. 3B). Consistent with their ability to inactivate and
sequester ERK in their respective cellular locations, DUSP5NLS-
Myc and DUSP6-Myc reduced p-ERK and also the ERK N:C
ratio (Fig. 3B). To determine if the differential effects of these
DUSP-Myc transgenes could be due to altered expression kinet-
ics, we compared time courses of p-ERK responses to FBS at
varied Ad titers. Each of the DUSP-Myc proteins showed compa-
rable magnitude and kinetics of induction, but only DUSP5-Myc
was able to propagate cytoplasmic ERK activity. In contrast, both
DUSP5NLS-Myc andDUSP6-Myc potently and dose-dependently
decreased p-ERK throughout the cell (Fig. 3A and 3C). These
data suggest that DUSP5-mediated increases in cytoplasmic p-
ERK are dependent upon its nuclear localization.
DUSP5 propagates ERK signaling by relieving upstream
kinase inhibition. A major mechanism by which ERK self-limits
its activity is through direct phosphorylation and inhibition of
upstream components, such as RAS exchange factors (7), RTKs
(8, 9) and RAF kinases, which prevent RAS-mediated RAF
dimerization and activation (4–6). This rapid negative feedback
confers homeostatic control, such that pharmacological inhibi-
tion or a reduction in total ERK concentration cause strong
compensatory increases in upstream kinase activity, which acts
to maintain near constant p-ERK output levels (30, 36, 37).
We therefore hypothesized that the nuclear sequestration and
inactivation of ERK by DUSP5 may cause similar compensatory
increases in upstream kinase activity, and that this may explain
why cytoplasmic p-ERK levels are maintained or even prolonged
in the presence of DUSP5.
To assess whether our hypothesis was tenable, we devised
a simplified mathematical model to explore the nature of in-
teractivity between DUSP5, ERK and upstream kinases that
could cause DUSP5 to increase ERK signaling (Fig. 4A). In
this network, K (representing all kinases upstream of ERK), is
converted upon stimulus to an activated form, K*, which catalyzes
the conversion of ERK to an active form, ERK*. To replicate
typical receptor signaling, we modeled the conversion of K to
K* as being rapid, followed by slower exponential conversion
back to K. To represent rapid feedback inhibition of upstream
kinases, ERK* was able to accelerate the deactivation of K* in
ourmodel (Fig. 4A, S5Aand SIMaterials andMethods). Previous
studies indicate that ERK-mediated inhibition of RAF is chiefly
responsible for homeostatic control of the ERK cascade, and is
highly non-linear in nature (30, 36, 37). We therefore modeled
the relationship between ERK* and K* as highly cooperative by











































































































































Fig. 4. DUSP5 propagates ERK signaling by relieving upstream kinase
inhibition. (A) The cartoons show conceptual model network structures
comprising ERK activation by an upstream kinase (K), feedback inhibition
and sequestration of ERK by DUSP5, and non-linear feedback inhibition of
K by ERK. K* and ERK* denote activated forms of K and ERK, respectively.
The plots show model predictions of ERK* concentration versus time in
arbitrary units (AU) under conditions where there is 'No', 'Low' or 'High'
levels of DUSP5 and in which negative feedback between ERK and K is
intact (left) or completely disabled (right). (B) Wild-type (WT) and Dusp5
knockout (KO) MEFs were infected with either empty Ad, or Ad expressing
HA-ΔCRAF-ER, alongside either 0.3 or 3 pfu/nl of Ad EGR1 promoter-driven
DUSP5-Myc. Cells were stimulated with either 20% FBS (left) or 0.1 µM 4HT
(right) prior to immunostaining for TEY phosphorylated (p-) ERK andMyc-tag
followed by high content microscopy analysis. Normalized population mean
AFU values for whole-cell p-ERK and Myc intensity are shown ±SEM, n=6,
*p<0.05, **p<0.01 comparing KO vs KO+3.0 pfu/nl Ad DUSP5-Myc using 2-
way repeated measures ANOVA and Bonferroni post-test. (C) Representative
high content microscopy images are shown from experiments described in
(B), comparing Ad HA-ΔCRAF-ER-infected MEFs after 360 min stimulus with
0.1 µM 4HT. Scale bar = 100 μm
and Methods). As ERK induces DUSP5 expression (19, 20), we
modeled DUSP5 synthesis as dependent upon ERK*, but with
a delay to replicate the time lag incurred by transcription and
translation. Because DUSP5 differentially controls nuclear and
cytoplasmic ERK activity (Fig. 1), we initially included compart-
mentalization and ERK traffic in our model (SI Materials and
Methods).However, biological rates of ERKnuclear shuttling are
fast enough relative to the time scale of p-ERK propagation, that
their inclusion in the model did not influence in silico predictions
(Fig. S5B). Therefore, in ourmodel we assumed for simplicity that
all ERK associated with DUSP5 is inactive and that the release
of inactive ERKoccurs throughDUSP5 degradation (Fig. 4A and
SI Materials and Methods).
When K, ERK and DUSP5 enzymes were linked this way
in silico, increasing DUSP5 levels proportionally increased the
ERK* response (Fig. 4A), which qualitatively replicated the ki-
netics of FBS-induced p-ERK responses observed in cells, using
Dusp5 KO and rescue experiments in MEFs (Fig. 4B). Reduc-
ing the cooperativity of feedback between ERK* and K* in
our mathematical model caused reduced the ability of DUSP5
to propagate ERK* (Fig. S5A), while complete disruption of
feedback between ERK* and K* completely reversed DUSP5
function, such that increasing DUSP5 levels proportionally re-
duced ERK* (Fig. 4A, compare left and right plots). These
mathematical simulations suggest that the effects of DUSP5 are
reliant upon the relief of upstream feedback mechanisms. To
test this prediction, we generated Ad expressing an HA-tagged
fusion protein of the conserved region 3 (CR3) kinase domain
of CRAF (residues 305-648), and the estrogen receptor ligand-
binding domain (HA-ΔCRAF-ER). The CR3 region of CRAF
lacks five (of six) inhibitory ERK phosphorylation sites (4), and
is therefore insensitive to feedback inhibition (30). HA-ΔCRAF-
ER also lacks an N-terminal auto-inhibitory domain, while the
fusion to ER renders it conditionally activatable by the addition
of 4-hydroxytamoxifen (4HT) (38). Accordingly, stimulation of
MEFs expressing HA-ΔCRAF-ER with 4HT caused rapid, sus-
tained increases in p-ERK (Fig. 4B and C). Under these condi-
tions, DUSP5 dose-dependently reduced p-ERK levels in both
the nucleus and cytoplasm, mimicking the predictions generated
in our mathematical model (compare Fig. 4A, B and C). These
data indicate that key aspects of DUSP5 function, and specifically
its ability to promote ERK activity, are dependent upon the relief
of upstream negative feedback within the ERK cascade.
DUSP5 degradation controls the amplitude and duration
of ERK activity. Published estimates of DUSP5 half-life are in
the order of 45 min (20), but how this rapid turnover in-
fluences ERK regulation is unclear. We employed our math-
ematical model to predict the effects of altering DUSP5 half-
life, and found that abrogating DUSP5 degradation reduced
the amplitude of sustained ERK* signaling in silico (Fig. 5A).
To test this prediction, we reconstituted Dusp5 KO MEFs with
supraphysiological levels of either DUSP5-Myc or DUSP5R53/54A-
Myc, and used a proteasome inhibitor (MG132) to block DUSP5
degradation 120 min after FBS stimulation. MG132 blocked the
degradation of DUSP5-Myc and caused a corresponding increase
in ERK nuclear accumulation (ERK N:C ratio; Fig. 5B), but
reduced p-ERK signal propagation by up to 50% (Fig. 5B and
5C). In contrast, DUSP5R53/54A-Myc did not influence p-ERK
responses or ERK N:C ratio, replicating the 'No DUSP5' condi-
tions in our mathematical model (Fig. 5B). Importantly, MG132
addition to cells expressing DUSP5R53/54A-Myc did not influence
p-ERK signaling, indicating that its effects in cells expressing
DUSP5-Myc arise specifically because the interaction between
ERK and DUSP5 is prolonged (Fig. 5B). Controls using MEKi
addition after 120 min reduced p-ERK and ERK N:C to basal
levels within minutes, indicating that continuous MEK activity
is required for DUSP5 to propagate ERK signaling and cause
continuous ERK nuclear accumulation (Fig. 5B). Taken together,
these data support a model where DUSP5 firstly sequesters de-










































































































































Submission PDFFig. 5. DUSP5 degradation controls the amplitude and duration of ERK signaling.(A) The cartoons depict a ‘normal’ network structure (left) and one inwhich DUSP5 degradation is abrogated (right). The plot compares model simulations for conditions where DUSP5 is synthesized and degraded (DUSP5), where
DUSP5 is absent (No DUSP5) or synthesized but not degraded (Non-deg DUSP5). Comparisons of activated ERK (ERK*) concentrations versus time are shown
in arbitrary units (AU). Note: the break in the x-axis is to enable direct comparison with the wet-lab data shown in (B), in which only prolonged phases
(>120 min) of FBS stimulus were measured. (B) Dusp5 knockout (KO) MEFs were infected with 3 pfu/nl of adenovirus (Ad) expressing EGR1-promoter driven
DUSP5-Myc or DUSP5R53/54A-Myc prior to 20% FBS stimulus for 120 min and treatment with either DMSO vehicle, 10 μM MG132 proteasome inhibitor, or 5
μM PD0325901 MEK inhibitor (PD). Plots show high content microscopy readouts for whole-cell p-ERK, ERK nuclear:cytoplasmic ratio (N:C) and whole-cell Myc
intensity and are shown as normalized population mean AFU ±SEM, n=3. *p<0.05, **p<0.01 using 2-way ANOVA and Bonferroni post-test comparing DMSO
and MG132-treated cells.(C) Representative images are shown from high content microscopy experiments described in (B). Scale bar = 100 μm.
kinase inhibition, and that the subsequent degradation of DUSP5
releases ERK from the nucleus, causing a rebound in p-ERK
levels.
DUSP5 facilitates BRAFV600E-driven cell proliferation and
transformation. The oncogenic V600E substitution in BRAF
causes constitutive kinase activation, irrespective of RAS activa-
tion or dimerization status (5). As such, BRAFV600E is refractory
to feedback inhibition by ERK (26, 30, 36, 37). In contrast,
RASmut oncoproteins constitutively activate the ERK pathway,
but leave ERK-RAF negative feedback intact. We therefore hy-
pothesized that DUSP5 would cause more profound effects on
p-ERK signaling in the presence of BRAFV600E than RASmut. To
test this, we expressed comparable levels of HA-BRAFV600E or
HA-HRASQ61L in WT and Dusp5 KO MEFs (Fig. S6) prior to
FBS stimulation, and rescued DUSP5-Myc expression to normal
or supraphysiological levels. In control cells lacking oncogene
expression, DUSP5 again propagated FBS-induced p-ERK lev-
els. HA-HRASQ61L expression marginally increased basal and
FBS-induced p-ERK levels, but neither Dusp5 KO nor rescue
significantly influenced responses (Fig. 6A). In contrast, HA-
BRAFV600E expression caused high p-ERK signaling irrespective
of FBS stimulus, and Dusp5 deletion further elevated p-ERK
levels by 30%, which was dose-dependently inhibited by Ad
DUSP5-Myc rescue at all time points (Fig. 6A). These data sug-
gest that the loss of negative feedback caused by either ΔCRAF-
ER or BRAFV600E expression is sufficient to transform the regu-
latory function of DUSP5, from a cytoplasmic propagator to cell-
wide inhibitor of ERK (compare Fig. 4B and 6A).
In the absence of other genetic mutations, RASmut or
BRAFV600E expression can cause ‘oncogene-induced’ cell cycle
arrest and senescence, which is mediated by hyperactivation of
ERK and consequently limits cell transformation (16, 39–41).
We have previously shown that Dusp5 KO does not influence
HRASQ61L-mediated MEF proliferation or transformation (22),
but reasoned that the more pronounced effects of Dusp5 KO on
BRAFV600E signalingmight be sufficient to mediate such changes.
To test this, we performed colony formation assays in WT and
Dusp5 KO MEFs immortalized by targeted Cdkn2a knockdown
(22) and expressing either HRASQ61L or BRAFV600E. Both onco-
genes induced comparable transformation rates inWTMEFs, but
Dusp5 KO selectively abolished BRAFV600E-driven transforma-
tion (Fig. 6B). To establish whether these effects were accompa-
nied by a similar influence on proliferation, we compared rates
of S-phase entry 24 h after addition of HA-HRASQ61L or HA-
BRAFV600E. As nuclear ERK activity is required for proliferation
(42) and because the effects ofDusp5KOonBRAFV600E signaling
were most apparent in the nucleus, we specifically compared nu-
clear p-ERKwith rates of S-phase entry.Dusp5KO caused a 25%
increase in HA-BRAFV600E-induced nuclear p-ERK and a cor-
responding 50% drop in S-phase positive cells (Fig. 6C). Partial
blockade of p-ERK signaling in HA-BRAFV600E+Dusp5KO cells
using sub-IC50 (0.1 µM) MEKi, completely restored rates of S-
phase entry, while more complete p-ERK inhibition using higher
MEKi concentrations (> 1 μM) caused a complete cessation
of proliferation (Fig. 6C). In either control populations without
oncogene or HA-HRASQ61L-expressing populations, Dusp5 KO
had no significant effect on nuclear p-ERK responses, S-phase
entry or MEKi efficacy (Fig. 6C). These data are consistent with
studies indicating that only a narrow range of ERK activity can
promote cell cycle progression (14, 41), and suggest that Dusp5
KO+BRAFV600E increases ERK activity beyond thresholds that
are compatible with cell proliferation.
In order to test whether the effects of Dusp5 deletion seen
on proliferation rate reflected a particular subpopulation of cells,











































































































































Fig. 6. BRAFV600E expression combined with Dusp5 deletion causes ERK hyperactivation and proliferative arrest. (A) Primary wild-type (WT) and Dusp5
knockout (KO) MEFs were infected with empty adenovirus (Ad), Ad HA-HRASQ61L or Ad HA-BRAFV600E alongside 0.3-3 pfu/nl of Ad expressing EGR1 promoter-
driven DUSP5-Myc prior to stimulation with 20% FBS. Plots show time courses comparing whole-cell p-ERK levels using high content microscopy. Normalized
population mean AFU values are shown ±SEM, n=4. *p<0.05, **p<0.01 comparing KO vs KO+3.0 pfu/nl Ad DUSP5-Myc using 2-way repeated measures ANOVA
and Bonferroni post-test. (B) Immortalized WT and Dusp5 KO MEFs were infected with retrovirus control, HRASQ61L or BRAFV600E vectors for 2 weeks prior to
assessment of transformed foci using methylene blue staining. Representative plate scans are shown and plots show average focus formation/well ±SEM, n=4.
**p<0.01 comparingWT vs KO using 2-way repeated measures ANOVA and Bonferroni post-test. (C) PrimaryWT and Dusp5 KOMEFs were infected with either
empty Ad, Ad HA-HRASQ61L or Ad HA-BRAFV600E and treated with increasing doses of PD0325901 MEK inhibitor for 24 h prior to a 2 h ﬂuorescent EdU pulse
label, immunostaining for p-ERK and analysis using high content microscopy. Plots show nuclear (Nuc) p-ERK levels and the percentage of EdU positive cells
±SEM, n=3. **p<0.01 using 2-way repeated measures ANOVA and Bonferroni post-test comparing WT and KO. Representative images are shown beneath.
Scale bar = 200 μm. (D) WT and Dusp5 KO primary MEFs were infected with Ad HA-BRAFV600E (top row), Ad HA-HRASQ61L (bottom row) and 0.3 pfu/nl Ad
DUSP5-Myc and treated with 0.1 µM PD0325901 (PD) as indicated for 24 h prior to 2 h ﬂuorescent EdU pulse labeling of S-phase cells and counterstaining
for p-ERK and HA-tag. The plots show HA intensity versus Nuc p-ERK in single cells; contour lines show equal cell density and the heat map reﬂects the
percentage of S-phase positive cells within HA and p-ERK bins. Data plotted are in raw AFU and population statistics, including mean p-ERK levels, p-ERK
standard deviation (SD) and overall percentage of S-phase positive cells are shown in within individual plots.
phase entry in single cells. We found that Dusp5 deletion selec-
tively increased nuclear p-ERK and reduced S-phase entry across
a 10-fold difference in HA-BRAFV600E (but not HA-HRASQ61L)











































































































































Fig. 7. Dusp5 deletion accelerates BRAFV600E-driven senescence in MEFs
and cancer cell lines.(A) Wild-type (WT) and Dusp5 knockout (KO) primary
and immortalized MEFs were infected with empty adenovirus (Ad), Ad HA-
HRASQ61L, Ad HA-BRAFV600E and Ad EGR1-promoter driven DUSP5-Myc (Ad
DUSP5) and treated with 0.1 µM PD0325901 (PD) MEK inhibitor as indicated.
Representative images show senescence-associated □β–galactosidase (SA
β–gal) staining of MEFs after 72 h. Scale bar = 125 μm. The quantiﬁcation of
SA β–gal staining is shown for primary MEFs after 72 h ±SEM, n=4. **p<0.01
using 2-way repeated measures ANOVA and Bonferroni post-test. Western
blots compare indicated protein levels in primary MEFs 24 h after oncogene
expression.(B) The plots show qPCR comparisons of indicated mRNA levels
from primary MEFs treated as in (A) for 24 h. *p<0.05, **p<0.01 using 2-way
repeated measures ANOVA and Bonferroni post-test.(C) Model depicting
cellular consequences of combined BRAFV600Eexpression and DUSP5 deletion.
response (reflected by the increased spread of p-ERK histogram
contours and standard deviation values; Fig. 6D). Addition of
Ad DUSP5-Myc or 0.1 µM MEKi reversed the effects of Dusp5
KO+HA-BRAFV600E on nuclear p-ERK levels, heterogeneity and
S-phase response (Fig. 6C, 6D and S7). Our data therefore sup-
port a model where proliferation of cells is robust to disruption of
a single feedback loop by either BRAFV600E expression or Dusp5
deletion, but their combinatorial loss increases both the intensity
and heterogeneity of the p-ERK response to such an extent that
proliferation is inhibited.
DUSP5 deletion accelerates BRAFV600E-driven senescence.
Finally, we investigated whether DUSP5 was able to influ-
ence HRASQ61L or BRAFV600E oncogene-induced senescence.
As expected, expression of HA-BRAFV600E or HA-HRASQ61L in
primary and immortalized MEFs increased the proportion of
senescence-associated β-galactosidase positive cells (SA β-Gal+)
within 72 h by3.5 fold (Fig. 7A). However,Dusp5 deletion dou-
bled the HA-BRAFV600E-induced proportion of SA β-Gal+ cells,
which was reversed by 0.3 pfu/nl Ad DUSP5-Myc rescue or the
addition of 0.1 µMMEKi (Fig. 7A), suggesting that the onset of
senescence is accelerated byDusp5 deletion.We therefore sought
to establish if molecular changes associated with senescence (39)
were altered at earlier time points. Western blotting of whole
cell lysates showed that HA-BRAFV600E expression for just 24
h in primary Dusp5 KO MEFs caused a small, but not statisti-
cally significant, decrease in Cyclin A expression (Fig. 7A) and
markedly elevated levels of Cdkn1a (p21CIP1), Cdkn2a (p16INK4A)
and Serpine1 (PAI-1) mRNA (Fig. 7B). All of these changes were
entirely restored to levels seen in WT cells by Ad DUSP5-Myc
rescue or 0.1 µM MEKi, indicating that the elevation of these
senescence markers is both DUSP5- and MEK-dependent. No
such changes were seen when combining Dusp5 KO with HA-
HRASQ61L expression or in the absence of oncogene expression.
These data collectively suggest that in this MEF model of in-
cipient tumorigenesis, Dusp5 deletion accelerates BRAFV600E-
induced cell cycle arrest and senescence by causing ERK hyper-
activation.
Discussion
We demonstrate that DUSP5, a phosphatase that is induced by
ERK activity and specifically inactivates and anchors ERK in the
nucleus (19–22), can also increase cytoplasmic ERK activation
(Fig. 1). These positive effects of DUSP5 are dependent upon the
relief of upstream kinase inhibition (Fig. 2 and 4), the nuclear
localization of DUSP5 (Fig. 3) and rapid DUSP5 degradation
(Fig. 5). Expression of the BRAFV600E oncogene, which is present
in 8% of all human tumors (43) and is refractory to ERK feed-
back inhibition (5, 26), reprograms the regulatory role of DUSP5
to facilitate cell proliferation and transformation (Fig. 6 and 7).
Critically, these data show that members of the MKP/DUSP
family can exert substantial effects through 'feedback relief' as
a consequence of their interaction with target MAPKs. As most
MKP/DUSPs have distinct MAPK substrate affinities, half-lives
and promoter regulation (10, 11), our data have important con-
sequences for understanding how the MKP/DUSPs influence
MAPK signaling in different contexts, including malignant pro-
gression.
Whilst our data show that DUSP5 can propagate ERK sig-
naling in response to sustained stimuli, such as serum, TPA or
NGF (Fig. 1 and S3), it is likely that these effects are stimulus-
specific. For example, it is difficult to envisage amechanismwhere
DUSP5 could possibly extendERK signaling induced by transient
stimuli that are desensitized before significant levels of DUSP5
have been expressed (< 60 min). We used a conceptual three-
component mathematical model in our study, which mimicked
the propagation of ERK signaling by DUSP5 (Fig. 4, 5 and
S5A). A key predicted requirement for this signal propagation











































































































































upstream kinases by ERK (Fig. 4A). This prediction was tested
in cells using expression of either a conditionally activatable
ΔCRAF-ER fusion or the BRAFV600E oncogene, both of which
disable ERK-mediated feedback inhibition of RAF (26, 30) and
reversed the function of DUSP5, from propagator to inhibitor of
ERK activity (Fig. 4 and 6). Our data therefore suggest that the
regulatory effects of DUSP5 are profoundly dependent upon the
relief of feedback between ERK and upstream kinases. Thus, sig-
nals that cause ERK activation via MEK-activating kinases other
than RAF, such as Mos, MEKK1 (MAP3K1), and COT/Tpl2
(MAP3K8), which are not typically feedback inhibited by ERK
(12, 44), may also reverse the function of DUSP5 in a similar
manner to ΔCRAF-ER or BRAFV600E (Fig. 4 and 6).
The notion that DUSP5 (and likely other MKP/DUSPs)
should mediate effects through ‘feedback relief’ is perhaps to be
expected in light of the number of studies demonstrating that
pharmacological inhibitors of the ERK pathway cause similar
effects (25, 30, 36, 37, 45, 46). Our results indicate that the nuclear
sequestration of inactive ERK by DUSP5 evokes compensatory
increases in upstream RAF and MEK activation through feed-
back relief (Fig. 2A and S4), and that the release of ERK follow-
ing DUSP5 degradation causes a rebound in ERK activity (Fig.
5). Strikingly, we found that mutation of the nuclear localization
signal (NLS) of DUSP5, which impedes nuclear import (21),
causes potent inhibition of ERK throughout the cell. Similar
data were seen following expression of DUSP6 (a cytoplasmic
paralog of DUSP5 (11)), indicating that the nuclear localization
of DUSP5 is a requirement for its propagation of cytoplasmic
ERK activity (Fig. 3). These data are somewhat surprising, given
that the inclusion of cellular compartmentalization in our math-
ematical model made no difference to our in silico simulations
of ERK signal propagation by DUSP5 (compare Fig. 4A, S5A
and S5B). Our mathematical model is therefore predictive of
DUSP5 behavior when it is confined to the nucleus, but cannot
at present account for why cytoplasmic MKP/DUSPs may, in
contrast, attenuate ERK activity so potently. Nevertheless, our
experimental data clearly indicate that DUSP5 and DUSP6 play
distinct roles in regulatingERK that are likely attributable to their
subcellular distribution. Resolving the molecular basis for these
differences will be the subject of future investigation.
Our data indicate that, despite the fact that DUSP5 can
regulate both nuclear and cytoplasmic ERK signaling ((22) and
Fig. 1), its deletion does not obviously influence normal cell
proliferation in primary or immortalized MEFs (Fig. 6). Fur-
thermore, mice entirely lacking DUSP5 develop normally and
display no obvious adult phenotype (22), suggesting that the
physiological role of DUSP5 may only be fully apparent in the
event of stress or pathological challenge. In support of this, our
previous data demonstrate that DUSP5 suppresses HRASQ61L-
driven tumors in a DMBA/TPA chemical carcinogenesis model
(22). Our current study also supports this view by showing that
DUSP5 facilitates BRAFV600E-driven cell proliferation and trans-
formation by preventing ERK hyperactivation and senescence
in MEFs (Fig. 6 and 7). These data may explain why DUSP5 is
typically retained or even elevated in cells derived from advanced
BRAFV600E tumors (25, 26). Our findings also support a growing
body of evidence demonstrating that both normal and tumor cells
are under strong selection pressure to maintain ERK activity
within a narrow threshold range, such that both ERK inhibition
and hyperactivation may cause tumor suppression (14, 15, 18,
41). It is therefore possible that the inhibition or loss of DUSP5
may have beneficial effects in BRAFV600E tumors by causing ERK
hyperactivation, as has been demonstrated for DUSP6, whose
inhibition or deletion causes senescence in BCR-ABL-driven
adult lymphoblastic leukemia (17).
The data in our present study indicates that Dusp5 deletion
can alter MEK inhibitor efficacy (Fig. 6C). Future work will
therefore focus on the possible interactions between DUSP5 and
chemical inhibitors of ERK pathway components in order to
better inform personalized therapy. While it is logical to test
compounds already in clinical use, it will be important to also
examine emerging ERK-targeted compounds that are reported
to act by inhibiting ERK dimerization (47) or nuclear transloca-
tion (48), as well as explore the possibility that DUSP5-specific
inhibitors may be developed. It is likely that the most effective
extension of our current work will be to determine the effects of
Dusp5 loss in human cancer cell lines with different oncogenic
backgrounds combined with the use of murine models that allow
tissue-specific conditional expression of BRAFV600E combined
with Dusp5 deletion to further define the in vivo significance of
our results. Finally, DUSP5 has recently been shown to regulate
ERK-dependent gene expression and survival in eosinophils and
to modulate responses to helminth infection in mice (49). The
latter results indicate that the relevance of our work may extend
beyond the regulation of oncogenic signaling to other diseases in
which abnormal ERK activity has been implicated. These include
inflammatory disease, cardiac hypertrophy, metabolic disorders
and neurodegenerative conditions, such as Alzheimer’s disease
(50–53).
Experimental Procedures
Cell Culture and Viral Infection. Primary and immortalizedMEFswere derived
and cultured as previously described (22). PC12 cells (a kind gift from Dr.
Shelley Allen, University of Bristol, UK) were maintained in RPMI 1640
medium containing GlutaMAX (Invitrogen), 5%horse serum (Invitrogen) and
10% fetal bovine serum (Invitrogen) in ﬂasks coated with type I collagen
from rat tail (Sigma). For experiments, cells were infected with Ad vectors
for 4-6 h.
High ContentMicroscopy and Analysis. Cells were immunostained in 96-
well black-wall imaging plates (Corning, 3904) as previously described (22)
and imaged using an IN Cell Analyzer 2000 (GE Healthcare) microscope using
a 10x or 20x objective lens, typically acquiring 500-2000 individual cells (2-6
ﬁelds) per well in duplicate or triplicate wells per condition. All exposures
were set such that signals were >30 AFU above background and maximal
<500 AFU below the maximum dynamic range. S-phase pulse labeling ex-
periments were carried out using 10 μM EdU ﬂuorescent thymidine analog
(5-ethynyl-2'-deoxyuridine, EdU) for 2 h prior to cell ﬁxation and detected
using a Click-iT® EdU Alexa Fluor® 647 HCS Assay kit (Invitrogen), according
to manufacturer’s instructions. In multiplex assays, EdU Alexa Fluor® 647
detection was carried out prior to antibody staining. Analysis was performed
using IN Cell Developer software (GE Healthcare) and a custom algorithm
using DAPI and p-ERK images to deﬁne nuclear and cytoplasmic regions,
respectively, which were used as a binary mask applied to images from all
ﬂuorophores to derive measures on a per cell, per compartment basis.
Details of all other methodology used, including vector manufacture
and mathematical modeling, are detailed in SI Materials and Methods.
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